January 22, 2009- NewCardio Inc., a cardiac diagnostic and services company, announced its membership in the Cardiac Safety Research Consortium (CSRC), a broad-based collaboration of medical product safety experts from academia, industry and the FDA.
The CSRC was formed in 2005 in response to the Critical Path Initiative, the FDA's premier effort to modernize the drug development process. The CSRC's primary goal is to facilitate development of new tools to improve cardiac safety assessment of medical products, especially tools to quantify arrhythmia risk of new drugs in development. With the FDA, the CSRC established a centralized ECG warehouse of ECGs obtained from drug clinical research studies.
As a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead ECG, NewCardio intends to be an active participant in CSRC efforts, by providing expertise and technology as needed, and by conducting targeted research and development projects, as such projects are reviewed and approved by the CSRC's Scientific Oversight Committee.
"We welcome NewCardio's participation in the CSRC. NewCardio offers a firm commitment to advancing the CSRC's goal of improving cardiac safety, and in so doing has a unique opportunity to demonstrate the utility of its novel technology resources and expertise. We hope to have a long and productive relationship with the Company," said Mitchell W. Krucoff, M.D., professor of cardiovascular medicine at Duke University and CSRC co-chair.
For more information: www.newcardio.com.
March 06, 2026 
